Bradykinin, infused in low doses (10 f.Lg/kg/ min) through the carotid artery ipsilateral to RG2 glioma in rats, significantly increased the permeability in tumor capillaries to six different tracers of varying molecular weights compared with intracarotid infusion of saline alone. Permeability in normal brain capillaries was not significantly increased by intracarotid bradykinin infu sion. Tracers used to examined permeability included ra diolabeled a-aminoisobutyric acid (AlB; MW 103), su crose (MW 342.3), inulin (MW 5000), and dextran (MW 70,000), horseradish peroxidase (HRP) and Evans blue (EB). Permeability was expressed as the unidirectional transfer constant Kj (f.LI/g/min). The permeabilities (Kj) of tumors in the bradykinin group versus the control saline group for AlB, sucrose, inulin, and dextran were 25.91 ± 6.78 vs. 13.95 ± 4.29
Brain tumor capillaries have a blood-tumor bar rier that limits adequate delivery of antitumor agents to tumor tissue and the immediately adjacent brain (Fenstermacher and Cowles, 1977; Groothuis et aI., 1982; Neuwelt et aI., 1982) . To increase drug delivery into the brain parenchyma, intracarotid in fusions of mannitol have been employed to open the blood-brain barrier (BBB) in animals (Tomiwa et aI., 1983; Neuwelt et aI., 1985) and humans (Neu welt et aI., 1984; Neuwelt and Rapoport, 1984) . Al though hyperosmotic infusions will increase drug delivery across the barrier, this approach results in and 17 .84 ± 1.00 vs. 1.47 ± 1.24 (p < 0.001), respectively (mean ± SD). Permeability of RG2 gliomas to high mo lecular weight dextran (70,000) was 12-fold higher in the bradykinin group than in the saline infusion group. Intra carotid infusion of bradykinin did not significantly in crease the blood volume in tumor or brain tissue despite its known vasodilative effect. The permeability of normal brain capillaries was unaffected by intracarotid bradyki nin infusion. The increased permeability was reversed 20 min after stopping the intracarotid infusion. Electron mi croscopic and gross qualitative analysis was performed using HRP and EB. Intracarotid bradykinin infusion in creased HRP and EB within tumor tissue but not normal tissue. We believe that intracarotid infusion of bradykinin will be a useful technique for selective delivery of antitu mor compounds to brain tumors. Key Words: Bradyki nin-Brain tumors-Blood-tumor barrier.
only a 25% increase in permeability within actual tumor capillaries in contrast to a 10-fold increase in permeability of normal brain capillaries (Millay et aI., 1986) . This greatly increases the exposure of normal brain to the toxic effects of antitumor agents.
Normal brain capillaries appear to effectively re sist the efforts of some vasoactive compounds to increase their permeability. In contrast, brain tumor capillaries or injured brain capillaries appear to lose the ability to resist the effects of increased perme ability by these compounds (Black et aI., 1990; Chio et aI., 1992) . In previous studies, we demonstrated how intracarotid infusion of leukotriene (LT) C 4 se lectively increases the permeability in brain tumor capillaries without affecting the permeability in nor mal brain capillaries (Black et aI., 1990; Chio et aI., 1992) . We speculated that this effect was due in part to loss of -y-glutamyl transpeptidase (the enzyme that converts LTC 4 to LTD 4 ) in tumor capillaries. The effect of L TC 4 on brain tumor capillaries is, however, limited to small molecules, and LTC 4 can only slightly enhance the delivery of some water soluble drugs to brain tumors compared with the saline . This study describes how ,bradykinin selectively increases permeability in brain tumor capillaries. The selective increase in brain tumor capillaries by bradykinin is much greater than the increase by LTC 4 • Bradykinin re sults in a 12-fold increase in permeability to high molecular weight dextran; in contrast, LTC 4 does not increase permeability in tumors to dextran.
Bradykinin increases the vascular permeability of systemic capillaries and has hypotensive effects that may reduce cerebral blood flow (Alvarez et aI., 1992; Y ong et aI., 1992) . Moreover, high-dose bradykinin will induce breakdown of the normal BBB (Raymond et aI., 1986) . In contrast to high dose bradykinin infusions, this study reports the ef fect of low-dose bradykinin on the BBB and on tu mor permeability using several tracers of varying molecular weight. Intracarotid infusions of brady kinin may selectively enhance drug delivery to brain tumors.
MATERIAL AND METHODS
Female Wi star rats, weighing 150-200 g, were used for this study. Bradykinin, horseradish peroxidase (HRP), and Evans blue (EB) were obtained from Sigma. a-[1-14C]Aminoisobutyric acid (AlB; 57.6 mCi/mmol) and car boxyl-e4C]dextran (0.81 mCi/g) were obtained from New England Nuclear. [14C]Sucrose (363 mCi/mmol) and e4C]inulin (3.15 fLCilmg) were obtained from ICN (CA, U.S.A.).
Tumor inoculation
The RG2 glioma cell line was maintained in a mono layer culture in F12 medium with 10% calf serum. The rats were anesthetized with intraperitoneal pentobarbital (30 mg/kg). Glial tumors were implanted into the right hemisphere by intracerebral injections of 1 x 105 RG2 glioma cells in 5 fLl of (1.2% methylcellose) F12 medium using a Hamilton syringe. The coordinates used were 5 mm lateral to the bregma and 4.5 mm deep to the dural surface.
Intracarotid infusion procedures
Seventy-six rats were used in this study. Rats were divided into two groups: a bradykinin group treated with intracarotid infusion of 10 fLg/kg/min of bradykinin and a control group treated with intracarotid infusion of saline.
One week after tumor implantation, the rats were again anesthetized and a polyethylene (PE-IO) catheter was in serted retrogradely through the external carotid artery to the common carotid artery bifurcation ipsilateral to the tumor. The external carotid artery was then ligated. One femoral artery was cannulated to monitor systemic blood pressure and the other femoral artery was cannulated to withdraw arterial blood. Body temperature was main-tained at 37°C and arterial blood gases, blood pressure, and hematocrit were monitored. Animals with abnormal physiologic parameters were eliminated from this study.
Bradykinin or saline (control) was infused into the right carotid artery at a rate of 53.3 fLUmin for 15 min. In blood volume studies, 5, 14, and 14.5 min after the start of the intracarotid infusion, 100 fLCi/kg of [14C]dextran was in jected as an intravenous bolus to make the circulation time of dextran 10, 1, and 0.5 min, respectively. In re gional permeability studies, 5 min after the start of the intracarotid infusion, 100 fLCilkg of the tracer was in jected as an intravenous bolus. A peristaltic withdrawal pump was used to withdraw femoral arterial blood at a constant rate of 0.083 mUmin immediately after the injec tion of the tracer for the determination of serum radioac tivity.
Fifteen minutes after the start of intracarotid infusions, the animals were killed by decapitation and the brains were rapidly removed and frozen. The duration of the effect of intracarotid bradykinin infusion was examined at three different periods by changing the time of [14C]dex tran injection relative to the infusion of bradykinin. The three periods were as follows: 0-10 min during the intra carotid bradykinin infusion (n = 7), 0-10 min after the infusion (n = 6), and 10-20 min after the infusion (n = 6). The experiment was terminated at the end of each period.
Autoradiography
The frozen brains were mounted onto pedestals with M-1 embedding matrix, and 20-fLm coronal sections were cut with a cryotome. The sections were thaw-mounted onto coverslips, and autoradiograms were generated by co-exposing the sections on Kodak XAR-5 film with tis sue-calibrated 14C-standards for 2 weeks. The sequential section was stained with hematoxylin for correlation of areas of histologically verified tumor with autoradio grams. The regional radioactivity was measured in tumor, brain surrounding the tumor (BST; areas within 2-mm distance from the border of the tumor), ipsilateral cortex to tumor, contralateral cortex, ipsilateral white matter (WM), contralateral WM, ipsilateral basal ganglia (BG), and contralateral BG. Quantitative analysis of the re gional radioactivity was performed using a computer (Macintosh II) with a scanner (UMAX UC630) and the software Image 1.45 (NIH).
Ki value calculation
For quantitative autoradiographic examination, the re gional permeability was expressed by the unidirectional transfer constant Kj value (fLUg/min). The Kj value was calculated for four different tracers. The initial rate for blood-to-brain transfer was calculated by the following equation (Ohno et aI., 1978; Ziylan et aI., 1988) :
where Cbr is the parenchymal brain-tumor concentration of the tracer at the end of the experiment (dpm/g), Cbl is the blood concentration of the tracer at the end of the experiment (dpm/g), T is the duration of the experiment (min), and Cp] is the arterial plasma concentration (dpm/ mI). Cbr depends on Cpl' With a high molecule weight tracer, the Cpl is stable during the short experiment of 10 min. Therefore, Cbr and Cbl can be written as
is the volume distribution of tracer in the tis sue, and the V o (ILl/g) is the blood volume in the tissue. Usi�g Eqs. 2, Eq. 1 can be written as 
Influence on other organs
Aliquots of frozen lung, liver, and kidney were weighed and solubilized with tissue solubilizer (BTS-450; Beck man) in duplicate. The radioactivity in the solubilized tis sue was counted by scintillation counter. The influence of intracarotid bradykinin infusion on the other organs was briefly examined by an index as follows:
where Ct is the organ concentration of the tracer at the end of experiment (dpm/g), T is the duration of the ex periment (min), and Cpl is the arterial plasma concentra tion (dpm/ml). Therefore, f�CpI dt is the average arterial concentration during the experimental period. This for mula is similar to Eq. 1, but blood volume in the tissue was not considered in this formula.
Microscopic examination
Six rats were used in this study. After rat preparation, bradykinin (10 ILg/kg/min in saline; n = 3) or saline (con trol; n = 3) was injected into the right carotid artery for 15 min. Five minutes after the start of the intracarotid infusion, 20 mg/IOO g HRP was injected by an intravenous bolus (Nishio et aI., 1983) . Ten minutes after HRP injec tion, rats were perfused with a mixture of 2% glutaralde hyde and 2% formaldehyde in 0.1 M sodium phosphate buffer solution at pH 7.4 through the heart. After fixation, the brains were removed and cut to 40-lLm sections using a vibratome. The sections were preincubated for 15 min at room temperature in medium consisting of 10 ml 0.05 M Tris-HCl buffer (pH 7.4), 3,3'-diaminobenzidine tetra hydrochloride, and 0.02% hydrogen peroxide (Sigma). Sections were trimmed to the areas of interests, postfixed for 2 h in 2% osmium tetroxide with 0.1 M sodium phos- Vol. 14, No.5, 1994 phate, dehydrated, and embedded in plastic. Thin sec tions were made for observation under electron micros copy.
Macroscopic observation
Ten rats were used in this study. To examined whether bradykinin could selectively deliver albumin into tumors, EB was injected intravenously instead of radiolabeled tracers. After the preparation of rats, 2 mlikg of 2% EB was injected intravenously instead of radiolabeled trac ers. After the intracarotid bradykinin (n = 5) or saline (n = 5) infusion, the rat was perfused with 200 ml of phos phate buffer through the heart to wash out the remaining EB from the vessels. The brains were removed immedi ately and cut as coronal sections.
RESULTS

Effect of bradykinin on physiologic parameters
Bradykinin infused at a rate >20 ILg/kg/min (dis solved in 0.9% saline) reduced systemic blood pres sure in rats when given either intravenously or into the carotid. The lO-lLg/kg/min rate of intracarotid bradykinin infusion used in quantitative experi ments did not alter systemic blood pressure. Phys iological parameters, which included arterial blood pH, PaC02, and Pao2, were also monitored. These physiological parameters were not significantly changed by bradykinin infusion at a rate of 10 J.Lgl kg/min during experiments.
Blood volume in tumor and brain
The blood volume for the quantitative examina tion of permeability was calculated with a graphic method using e 4 C]dextran. The blood volumes in brain and tumor tissue were 1.1 and 2.3 ILlig, re spectively (Fig. 1) . The slope is the unidirectional transfer constant Ki (J.Ll/g/min). Ki was similar in these experiments whether calculated using the graphic method or the method of Ohno et al. (1978) and Ziylan et al. (1988) . The y-intercept indicates that the increased volume of distribution after bradykinin infusion results from increased perme ability and not from increased blood volume, The tumor blood volume was almost twice that of the brain, but the brain and tumor blood volumes were not significantly altered by intracarotid bradykinin infusion.
Regional permeability
The absolute Ki values obtained for the different substances are given in Table 1 . The Ki values were calculated using the method of Ohno et al. (1978) and Ziylan et al. (1988) . The permeability Ki in tu mors to e 4 C]dextran (MW 70,000) after bradykinin infusion (n = 7) was 12-fold higher than in controls (n = 9, P < 0.001; Fig. 2, left) . The Ki values for [1 4 C]dextran calculated previously corresponded Determination of blood volume in experimental brain tumors. Data were obtained from quantitative studies by changing the experimental duration of bradykinin infusion to 0.5, 1, and 10 min. By plotting the value of volume distribu tion (Vd; fl,1/g) and the value of the tracer concentration in tissue divided by the tracer concentration in the blood, the regression line was obtained. The slope of the lines indicates unidirectional transfer constant K; (fl,l/g/ml) and the y-inter cept of the lines indicates the blood volume in the tissue. Based on the slope of the solid line (bradykinin group), the K; value in tumors to [14C]dextran in the bradykinin group is 17.9 fl,1/g/min. Intracarotid bradykinin infusion changed per meability but not blood volume in the tissue. The blood vol ume in the tumor was 2.3 fl,1/g. The average blood volume in the brain was 1.1 fl,1/g. The control group is represented by the dotted line.
well with the Ki value derived from the graph in Fig.  1 . The permeability in tumors after bradykinin in fusion was also increased using [1 4 C]sucrose (MW 342.3) (p < 0.01) and e 4 C]inulin (MW 5,000) (p < 0.0 1) (Table 1) . Although the Ki value for [1 4 C]inulin after bradykinin infusion was higher than that for e 4 C]sucrose, the difference was not significant. As for e 4 C]AIB (MW 103), the Ki values in tumors and in BST after bradykinin infusions were increased (p < 0.0 1 and p < 0.05, respectively) (Fig. 2, right) . Brain within 2 mm of tumors was evaluated as BST since this tissue may be affected by tumor compres sion and vasoactive compounds released by the tu mor itself. The Ki for dextran, inulin, and sucrose was not, however, significantly increased in brain within 2 mm of tumors after bradykinin infusion. Bradykinin infusion did not increase permeability in any normal brain region >2 mm from tumor to any of the tracers tested. Low-dose bradykinin infusion selectively increases permeability in tumors to trac ers of varying size, but does not increase perme ability in normal brain. Permeability is also in creased to AIB in brain within 2 mm of tumor after bradykinin infusion.
Effect on permeability in tumors to tracers of varying size
When the Ki values in tumors for all tracers were plotted against the size of the tracers after saline infusion, a general decline in Ki was observed as the molecular weight of radiolabeled tracers increased (Fig. 3) . The Ki in tumors after bradykinin infusion also showed a decline with increasing molecular weight of tracers, but the slope of the decline after bradykinin infusion was much less than in the con trol group. The relative effect of bradykinin on in creasing permeability therefore is much greater as the size of the tracer increases.
Time course of intracarotid infusion
The effect of intracarotid infusion was examined at three different time periods with e 4 C]dextran. The effect of bradykinin on tumor permeability was diminished 20 min after stopping the intracarotid bradykinin infusion (Fig. 4 ). This result indicates the effect of intracarotid bradykinin infusion is rap idly reversible.
Influence on other organs
Whether intracarotid bradykinin infusion in creased the uptake of e 4 C]sucrose and e 4 C]inulin in lung, liver, and kidney was also examined in rats used to calculate Ki in brain tumors (Table 2) . Com pared with the controls, bradykinin infusion did not significantly increase the uptake of tracers in lung, liver, or kidney.
Microscopic examination
Electron microscopic evaluation was performed using HRP. Some HRP staining was seen in con trols in the intercellular spaces (Fig. 5A ). In con trast, there was significant HRP staining surround ing capillaries and in intercellular spaces between tumor cells after bradykinin infusion (Fig. 5B ). In tracarotid bradykinin infusion selectively delivered HRP (MW 40,000) into tumor tissue. There was no leakage of HRP in normal brain tissue after either saline or bradykinin infusion (Fig. 5C ).
Macroscopic observation
EB staining was well recognized in tumor but not normal brain tissue after bradykinin infusion. Much less staining was seen in tumors in controls (Fig. 6) . Intracarotid bradykinin infusion selectiyely in creased the delivery of EB-bound albumin to tu mors. DISCUSSION We previously reported that intracarotid infusion of LTs could selectively increase permeability in brain tumors. Increased tumor permeability by 17.84 ± 0.99c 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.02 ± 0.05 0.00 ± 0.00
Values are means ± SD. ipsi, ipsilateral; Contra., contralateral cortex; for other abbreviations see the text.
Significant values (compared with same region): ap < 0.05, bp < 0.01, cp < 0.001.
LTs, however, is limited to small molecules (Black et al., 1990; Black and Chio, 1992; Chio et al., 1992) . While LTs increased permeability to AlB, which has a molecular weight of 100, permeability was not increased to inulin or dextran. In the present study, we have observed that intracarotid infusion of low-dose bradykinin increases tumor permeability to both large and small molecular trac ers.
Bradykinin is known to increase the vascular per meability of systemic capillaries (Alvarez et al., 1992; Yong et al., 1992) . Bradykinin also has va sodilative effects and reduces systemic blood pres sure, which could alter the cerebral blood flow. Therefore, a dose of bradykinin that did not alter the systemic blood pressure after intracarotid infu sion was determined. Blood volume in tumor and normal brain was determined after bradykinin infu sion using a graphic method with e 4 C]dextran. In tracarotid bradykinin infusion at the dose of 10 I-Lg/ kg/min did not alter systemic blood pressure or blood volume in either tumor or normal brain de spite its known vasodilative effects.
Intracarotid infusion of low-dose bradykinin se lectively increased permeability in brain tumors to e 4 C]AIB, e 4 C]sucrose, e 4 C]inulin, and e 4 C]dex tran by 1.8-, 1.6-, 3.8-, and 12-fold, respectively. The molecular weights of most antitumor com pounds range from 100 to 40,000. Most antitumor agents would therefore be within the molecular weight range of the six tracers used in this study. Interestingly, high molecular weight agents, which are the most difficult to deliver to brain tumors, may be the compounds most beneficially affected by bradykinin opening of the blood-tumor barrier.
We believe that, like LTs, bradykinin infusion may also increase permeability in abnormal (nontu mor) brain tissue. It is not unexpected, therefore, that bradykinin infusion would significantly in crease permeability in brain tissue within 2 mm of J Cereb Blood Flow Metab, Vol. 14, No. 5, 1994 experimental brain tumors to AlB. Tissues within 2 mm of tumors are affected by tumor mass effect and may also be affected by vasoactive compounds re leased by the tumor itself, such as LTs (Black et al., 1986) . The permeability for tracers larger than AlB was not increased by bradykinin in brain within 2 mm of tumor. Importantly, in normal brain >2 mm from tumor, permeability was not increased to any of the tracers by low-dose bradykinin infusion.
One argument that has been made for osmotic opening of the BBB is that it opens the barrier in normal brain tissue. Since malignant glial tumor cells are well known to infiltrate into these "nor mal" areas, Neuwelt et al. point out the importance of drug delivery beyond the main tumor mass (Neu welt et aI., 1984; Neuwelt and Rapoport, 1984) . Our studies, however, demonstrate that bradykinin in fusion can increase permeability in experimental tu mors as small as 1-2 mm. This is smaller than mi croscopic foci of tumor that can be detected by cur rent clinical magnetic resonance scanners. We believe that bradykinin opening of the tumor barrier will therefore increase permeability in small micro scopic tumor foci distant from the main mass of tumor. The advantage of bradykinin opening is the large 12-fold increase in tumor permeability to large molecules in contrast to the small 25% increase in tumor permeability with osmotic barrier opening. In addition, in normal brain without tumor, osmotic opening increases permeability 1O-fold, exposing this brain to the toxic effects of the antitumor agents. Low-dose bradykinin infusion does not in crease permeability in normal brain, and toxicity to normal tissue can be reduced.
In this study, we did not ligate the pterygopala tine artery, which is a large branch of the internal carotid artery in rats. Therefore, a large part of the substance injected might go to extracerebral tissues in our methods. This might be one explanation for the rather large standard deviations with the various Regional Kj values. Each bar indicates mean ± SO. A:
Regional Ki value of C4Cjdextran (MW 70,000). In tumors, the Ki value in the bradykinin group (shaded bar, n = 7) was 12-fold higher than in the control group (open bar, n = 9) (17.84 ± 1.00 vs. 1.47 ± 1.24; p < 0.001). The Ki values of normal brain regions in both groups were low and there were no significant differences between two groups. B: Regional Ki value of [14Cjaminoisobutyric acid (MW 103). The Ki values were significantly increased in tumors and brain surrounding tumor (8ST; areas at 2-mm distance from the border of the tumor) (p < 0.01 and p < 0.05, respectively), while the Ki values in normal brain regions >2 mm from tumors were not different between the bradykinin (n = 7) and control (n = 11) groups. Other regions contain ipsilateral cortex, contralater al cortex, ipsilateral white matter, contralateral white matter, ipsilateral basal ganglia, and contralateral basal ganglia.
tracers. Ligation of the pterygopalatine artery may result in more consistent data. Several mechanisms can account for increased BBB permeability. This include (a) increased vesic ular transport, (b) increased transcellular penetra tion, and (c) increased opening of the tight junctions There was also a decline in Ki with bradykinin between u-ami noisobutyric acid and the other tracers. However, Ki did not significantly decline after bradykinin with increasing molec ular weights between 342.3 and 70,000. of brain endothelial cells (Chan et al., 1983) . The concept of size-dependent (pores) and size-in dependent (vesicles) transport systems in cerebral vessels has been examined by Ziylan et al. (1983) . They showed a size-dependent increase in transport of different molecules caused by intracarotid injec tions of 1.8 M arabinose and concluded that in- The Ki values in tumors were examined at three different time periods: 0-10 min during intracarotid bradykinin infusion, 0-10 min after the infusion, and 10-20 min after the infusion. Means ± SO of Ki value are shown. The solid line parallel to the x-axis is the Ki value (1.47) in tumors in the control group. The Ki value 20 min after the infusion is not significantly different from that in the control group. creased transport after a hyperosmoiar solution is due to both separation of tight junctions and in crease in a size-independent transport mechanism, such as vesicular transport. Figure 3 shows the re lationship between Kj values within tumors and mo lecular size of the tracers. The permeability without bradykinin infusions declines with increasing mo lecular size of tracers (size dependent). In bradyki nin-infused animals, the Kj value in tumors de creases between AlB and the other tracers of larger size, suggesting size-dependent transport (between AlB and the other tracers). However, among su crose, inulin, and dextran, permeability is similar, suggesting size-independent transport (among su crose, inulin, and dextran). One interpretation of these findings is that increased permeability in con trol tumors results from opening of endothelial junc tions, and the increased permeability caused by bradykinin might result from both mechanisms.
Bradykinin has a short biological half-life because of proteolytic inactivation (Vanhoutte et aI., 1989; Erdos, 1990) . To determine the duration of the bradykinin effect on tumor capillary permeability, we measured the Kj at three different time periods. The degradation of bradykinin in rats is reported to be in the order of several hours (Kumakura et aI., 1988) . In the present study, the effect of bradykinin was diminished within 20 min after stopping the in tracarotid infusion. This shorter effect of bradyki nin on tumor capillary permeability may be due to both the selective intracarotid infusion and the lower dose of bradykinin used. The short effect on tumor capillaries of intracarotid infusion of brady kinin is, in fact, desirable for the selective delivery of anticancer drug in the treatment of the brain tu mors.
The enzyme that degrades bradykinin is peptidyl carboxypeptidase kinase II, which is identical to angiotensin I converting enzyme (ACE) (Ng and Vane, 1967) . Williams et al. (199 1) , using antiserum to purified pig kidney ACE, reported that the pig brain capillary contained ACE. Moreover, the ACE inhibitor captopril enhanced the bradykinin effect (Yong et aI., 1992) . In very preliminary studies we examined whether rat brain capillaries contained ACE using antiserum to purified human kidney ACE. ACE was not recognized in the rat brain cap illaries in our studies, whereas this antiserum rec ognized ACE in the rat kidney cortex (data not shown). When intravenous captopril infusion was FIG. 5. Electron microscopic observation was performed using horseradish peroxidase (HRP) as the tracer. Some slight HRP staining in the control group was recognized in the intercellular spaces in the tumor tissue (A). In contrast, there was significant HRP staining surrounding capillaries and in the intercellular spaces between tumor cells in the bradykinin group (8). In normal brain tissue, there was no leakage of HRP from capillaries either in the control or in the bradykinin group (C). Bar = 2.5, 1.25, and 2.5 fLm (A-C).
FIG. 6. Coronal section showing Evans blue (EBl staining within tumor. EB was injected intravenously instead of ra diolabeled tracers. Ten minutes after EB injection. the rat was perfused with 200 ml of phosphate buffer through the heart to wash out the remaining EB from the vessels. EB is well visualized in tumor in the bradykinin group (A). The tu mor in the control group (8) and the normal brain tissue in both groups are not stained (A and Bl. used to enhance the effects of bradykinin on tumor permeability, hypotension occurred, which made it difficult for us to maintain normal systemic pressure during the experiment. Permeability values were not calculated under these conditions since blood flow may have been affected by the hypotension. Future studies are planned to further clarify these early findings.
We also examined the influence of intracarotid bradykinin infusion on the other organs. Lung, liver, and kidney are often damaged by treatment with anticancer drugs. It is more desirable that in tracarotid bradykinin infusion not deliver more tracers into the other organs compared with con trol. In these studies, there was no difference in the amounts of tracer in the organs examined. These data suggest that intracarotid bradykinin infusion will not increase drug delivery to other organs. Guillot and Audus (1990) reported that nanomolar concentrations of bradykinin stimulated the uptake of the fluorescent marker Lucifer yellow in brain capillary endothelial cells by 40%. Raymond et al. (1986) reported that high-dose intracarotid infusion of bradykinin (almost six times higher than our dose) caused extravasation of HRP around the nor mal brain capillary. In their study, they also recog nized vasodilatation of micros vessels and HRP en docytosis in endothelial cells. Although high-dose bradykinin will affect the normal endothelial perme ability, lower doses will selectively increase brain tumor permeability without increasing normal brain permeability.
This study examines the use of low-dose intraca rotid bradykinin infusion as a method to selectively deliver high molecular weight agents to brain tu mors. Intracarotid bradykinin infusion selectively increases the permeability in brain tumors for trac ers ranging in molecular weight from 100 to 70,000. The duration of the effect of intracarotid bradykinin infusion is �20 min. We believe that low-dose in tracarotid bradykinin infusion could be used to se lectively deliver antitumor compounds to brain tu mors.
